Journal article
Reliable genotypic tropism tests for the major HIV-1 subtypes
K Cashin, LR Gray, KL Harvey, D Perez-Bercoff, GQ Lee, J Sterjovski, M Roche, JF Demarest, F Drummond, PR Harrigan, MJ Churchill, PR Gorry
Scientific Reports | NATURE PORTFOLIO | Published : 2015
DOI: 10.1038/srep08543
Open access
Abstract
Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the CCR5-antagonist, maraviroc, from being more widely used in anti-HIV-1 therapy regimens is that the pre-treatment genotypic œ tropism tests to determine virus susceptibility to maraviroc have been developed primarily for HIV-1 subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of HIV-1 genotypic tropism assays that are highly sensitive and specific for establishing the tropism of HIV-1 subtypes A, B, C, D and circula..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
We thank Rohan Gray for assistance with writing the code for the PhenoSeq algorithms and the bulk2clonal software, and Brendan Crabb for helpful comments. This study was supported by grants from (i) the Australian National Health and Medical Research Council (NHMRC) to P.R.G. and M.J.C. (1022066), (ii) the National Institutes of Health (NIH) to P.R.G. and M.J.C. (R21 MH100594), and (iii) the Delaney AIDS Research Enterprise (DARE) to M.J.C. and L.R.G. (U19 AI096109). K.Y.C. and K.L.H. are supported by Australian Postgraduate Awards from the University of Melbourne. P.R.G. is supported by an Australian Research Council (ARC) Future Fellowship (FT2). L.R.G. was supported by an Australian NHMRC Postdoctoral Training Fellowship. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.